1
Michael F Parker, Katharin E McElhone, Robert A Mate, Joanne J Bronson, Yonghua Gai, Carl P Bergstrom, Lawrence R Marcin, John E Macor: α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors. Bristol Myers Squibb Company, Aldo A Algieri, November 27, 2007: US07300936 (21 worldwide citation)

There is provided a series of novel α-(N-sulfonamido)acetamide compounds of the Formula (I) wherein R, R1, R2 and R3 are defined herein, which are inhibitors of β-amyloid peptide (β-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by anti-amyloid ac ...


2
Michael F Parker, Katharine E McElhone, Robert A Mate, Joanne J Bronson, Yonghua Gai, Carl P Bergstrom, Lawrence R Marcin, John E Macor: α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors. Bristol Myers Squibb Company, Aldo A Algieri, Pamela A Mingo, August 31, 2010: US07786122 (5 worldwide citation)

There is provided a series of novel α-(N-sulfonamido)acetamide compounds of the Formula (I) wherein R, R1, R2 and R3 are defined herein, which are inhibitors of β-amyloid peptide (β-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by anti-amyloid ac ...


3
Ivar M McDonald, Robert A Mate, James H Cook II, Dalton King, Richard E Olson, Nenghui Wang, Christiana I Iwuagwu, F Christopher Zusi, Matthew D Hill, Haiquan Fang, John E Macor: Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands. Bristol Myers Squibb Company, James Epperson, October 2, 2012: US08278320 (1 worldwide citation)

The disclosure provides compounds of formula I, including Ia, Ib, Ic, or Id, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous syst ...


4
Kimberley A Lentz, Rex Denton, James H Cook II, Ivar M McDonald, Dalton King, Richard E Olson, Nenghui Wang, Robert A Mate, Christiana I Iwuagwu, F Christopher Zusi, John E Macor, Matthew D Hill, Haiquan Fang: Aza-bicyclic amine N-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs. Bristol Myers Squibb Company, James Epperson, July 9, 2013: US08481555 (1 worldwide citation)

The disclosure generally relates to compounds of the following formula, including their salts, as well as compositions and methods of using the compounds. The compounds are prodrugs for ligands, agonists, and partial agonists for the nicotinic α7 receptor and may be useful for the treatment of vario ...


5
Ivar M McDonald, Robert A Mate, James H Cook II, Dalton King, Richard E Olson, Nenghui Wang, Christiana I Iwuagwu, F Christopher Zusi, John E Macor: Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands. Bristol Myers Squibb Company, James Epperson, August 13, 2013: US08507516 (1 worldwide citation)

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and ...


6
Michael F Parker, Katharine E McElhone, Robert A Mate, Joanne J Bronson, Yonghua Gai, Carl P Bergstrom, Lawrence R Marcin, John E Macor: α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors. Bristol Myers Squibb Company, Pamela A Mingo, August 20, 2013: US08513253

There is provided a series of novel α-(N-sulfonamido)acetamide compounds of the Formula (I) wherein R, R1, R2 and R3 are defined herein, which are inhibitors of β-amyloid peptide (β-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by anti-amyloid ac ...


7
Michael F Parker, Katharine E McElhone, Robert A Mate, Joanne J Bronson, Yonghua Gai, Carl P Bergstrom, Lawrence R Marcin, John E Macor: Alpha-(N-sulfonamido)acetamide derivatives as beta-amyloid inhibitors. Stephen B Davis, Bristol Myers Squibb Company, July 1, 2004: US20040127494-A1

There is provided a series of novel -(N-sulfonamido)acetamide compounds of the Formula (I) 1 wherein R, R1, R2 and R3 are defined herein, which are inhibitors of -amyloid peptide (-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by anti-amyloid act ...


8
Michael F Parker, Katharine E McElhone, Robert A Mate, Joanne J Bronson, Yonghua Gai, Carl P Bergstrom, Lawrence R Marcin, John E Macor: Alpha-(n-sulfonamido)acetamide derivatives as beta-amyloid inhibitors. Bristol Myers Squibb Company, Louis J Wille, Bristol Myers Squibb Company, April 10, 2008: US20080085894-A1

There is provided a series of novel α-(N-sulfonamido)acetamide compounds of the Formula (I) wherein R, R1, R2 and R3 are defined herein, which are inhibitors of β-amyloid peptide (β-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by anti-amyloid ac ...


9
Michael F Parker, Katharine E McElhone, Robert A Mate, Joanne J Bronson, Yonghua Gai, Carl P Bergstrom, Lawrence R Marcin, John E Macor: Alpha-(N-Sulfonamido)Acetamide Derivatives as Beta-Amyloid Inhibitors. Bristol Myers Squibb Company, May 5, 2011: US20110105485-A1

There is provided a series of novel α-(N-sulfonamido)acetamide compounds of the Formula (I) wherein R, R1, R2 and R3 are defined herein, which are inhibitors of β-amyloid peptide (β-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by anti-amyloid ac ...


10
Kimberley A Lentz, Rex Denton, James H Cook II, Ivar M McDonald, Dalton King, Richard E Olson, Nenghui Wang, Robert A Mate, Christiana I Iwuagwu, F Christopher Zusi, John E Macor, Matthew D Hill, Haiquan Fang: Aza-Bicyclic Amine N-Oxide Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligand Pro-Drugs. Bristol Myers Squibb Company, May 3, 2012: US20120108596-A1

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are prodrugs for ligands, agonists, and partial agonists for the nicotinic α7 receptor and may be useful for the treatment of various disorders ...